Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesOrdinary Fully Paid Deferred Settlement

Ordinary Fully Paid Deferred Settlement

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None AUD 0.00(0%)
Last update at 2026-06-01T06:45:07.606962Z
Market Cap
8.84M

Momentum Score

…

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treatment of acute myeloid leukaemia/colorectal cancer, acute myeloid cancer, blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors. The company was incorporated in 2020 and is based in Carlton, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.14
Low
0.24
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
9.75M
Revenue Per Share
0.39
Gross Profit TTM
8.90M
Debt / Equity
-
ROE
-1290.99%
Net Debt
0.54M
ROCE
-217.19%
Diluted EPS TTM
-0.84

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -10.32M -12.52M -25.41M -14.46M
Net income -10.43M -12.53M -25.50M -14.62M
Selling general administrative 7.05M 9.15M 11.92M 9.14M
Gross profit 3.12M - - -
Reconciled depreciation 1.03M 1.01M 0.97M 0.95M
Operating income -15.11M -21.02M -29.49M -17.19M
Interest expense 0.21M 0.33M 0.77M 0.64M
Tax provision 0.11M 0.01M 0.09M 0.16M
Interest income 0.05M 0.12M 0.03M 0.01M
Net interest income -0.16M -0.21M -0.75M -0.63M
Total revenue 3.97M - - -
Cost of revenue 0.85M - - -
Total other income expense net 4.95M 8.71M 4.83M 2.08M
Net income from continuing ops -10.43M -12.53M -25.50M -14.62M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 21.57M 15.27M 22.49M 35.76M
Intangible assets 11.04M 12.01M 12.98M 13.65M
Other current assets 0.22M 0.08M 0.03M 0.13M
Total liab 19.60M 16.40M 16.41M 9.33M
Total stockholder equity 1.97M 2.47M 6.08M 26.42M
Other current liab 3.56M 3.59M 3.14M 2.45M
Capital stock 70.16M 63.51M 53.93M 51.81M
Retained earnings -76.33M -66.56M -56.36M -29.59M
Cash 5.76M 3.05M 2.36M 18.38M
Total current liabilities 14.61M 13.69M 14.39M 9.02M
Net debt - 0.54M - -
Short long term debt - 3.59M - -
Total current assets 10.53M 3.22M 9.47M 22.05M
Long term investments - 0.04M 0.04M 0.04M
Net receivables - 0.09M 0.03M 3.54M
Accounts payable 6.57M 3.20M 7.41M 4.70M
Non current assets total 11.04M 12.05M 13.02M 13.71M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments - - - -0.04M -
Net borrowings - -2.28M -2.23M -4.09M -
Total cash from financing activities 10.05M 8.26M 0.25M 9.50M -
Net income -10.43M -12.53M -25.50M -14.62M -15.11M
Change in cash 2.77M 0.72M -16.16M -4.19M -
Begin period cash flow 3.05M 2.36M 18.38M 22.41M -
End period cash flow 5.76M 3.05M 2.36M 18.38M 22.41M
Issuance of capital stock 8.20M 11.74M 2.58M 14.90M -
Sale purchase of stock -0.57M -1.20M -0.09M -1.31M -
Capital expenditures 0.00M 0.00M 0.11M 0.54M 0.00M
Free cash flow -7.28M -7.54M -16.42M -13.67M -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CSL
CSL Ltd		 2.86
1.42%		 204.54 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.32
2.28%		 13.70 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.30
1.25%		 23.66 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.07
3.69%		 1.96 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Ordinary Fully Paid Deferred Settlement

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treatment of acute myeloid leukaemia/colorectal cancer, acute myeloid cancer, blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors. The company was incorporated in 2020 and is based in Carlton, Australia.

62 Lygon Street, Carlton, VIC, Australia, 3053

61 3 9824 5254

https://www.chimerictherapeutics.com

Name Title Year Born
Dr. Rebecca McQualter Chief Executive Officer NA
Mr. Aaron Laurita Chief Financial Officer NA
Dr. Stephanie H. Astrow MBA, Ph.D. Chief Scientific Officer 1962
Dr. Agathe Bourgogne Head of Manufacturing NA
Mr. Nathan Jong C.A. Joint Company Secretary NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…